Tiziana (TLSA) CEO Ivor Elrifi Converts 1.05M Derivative Shares

What Happened

• Ivor Elrifi, CEO of Tiziana Life Sciences (TLSA), reported the conversion/exercise of 1,050,000 derivative units into common stock on August 15, 2026 and a simultaneous disposition of the same 1,050,000 shares. No price per share or aggregate dollar value is provided (listed as N/A).

Key Details

• Transaction date: 2026-08-15 (reported on Form 4 filed 2026-09-29).
• Reported actions: Exercise/conversion of derivative (code M) — 1,050,000 shares acquired; 1,050,000 shares disposed (derivative).
• Price: N/A in the filing, so market value cannot be determined from this report.
• Shares owned after transaction: not disclosed in the provided filing excerpt.
• Footnotes: F1—each RSU equals a contingent right to one common share; F2—these RSUs were granted Aug 15, 2024 and vest in four annual installments (Aug 15, 2025–2028), including an installment on Aug 15, 2026.
• Timeliness: Form 4 was filed on 2026-09-29 reporting an 2026-08-15 transaction (filed well after the typical 2-business-day window), so the filing is late.

Context

• The filing shows both acquisition and immediate disposition of the same number of shares. That pattern commonly occurs when restricted stock units (RSUs) vest and shares are converted then surrendered or withheld (for taxes or settlement) or sold immediately; the filing’s footnotes identify the awards as RSUs with an August 15, 2026 vesting installment. Because no price or proceeds are listed, you cannot infer the financial impact or signal executive buying/selling intent from this single report.